| BUY | 51.490 | Norman Levine | In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together. | 2007-08-29 | |
| DON'T BUY | 45.110 | David Burrows | Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies. | 2005-08-25 | |
| TOP PICK | 40.000 | Harvey Eisen | Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story. | 2004-05-21 | |
| BUY | 44.020 | David King | Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals. | 2004-04-30 | |
| BUY | 41.750 | Brad Willock | Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive. | 2003-09-03 | |
| BUY | 55.500 | David Burrows | Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot | 2001-12-10 | |
| BUY | 42.563 | Noah Blackstein, B.A., CFA | Getting into acquisitions. Had to restructure. Moving from a value to a growth stock | 2001-01-08 | |
Experts that have talked about Abbott Labs
Rss Top Picks Feed
